Lymphohistiocytosis, Hemophagocytic
Showing 1 - 25 of 131
Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Recruiting
- Lymphoma
- Hemophagocytic Lymphohistiocytoses
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jun 1, 2023
Refractory, Recurrence, Hemophagocytic Lymphohistiocytosis Trial (GTP regimen)
Not yet recruiting
- Refractory
- +2 more
- GTP regimen
- (no location specified)
Sep 8, 2023
EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection Trial in Beijing (EBV-TCR-T cells)
Recruiting
- EBV-associated Hemophagocytic Lymphohistiocytosis
- EBV Infection
- EBV-TCR-T cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Nov 12, 2023
IFN? and Inflammatory Mediators in Hemophagocytic
Completed
- Hemophagocytic Lymphohistiocytoses
- Blood Draws Data Collection
-
Boston, MassachusettsBrigham and Women's Hospital
Sep 14, 2023
Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses Trial in Beijing (Carrimycin tablets)
Not yet recruiting
- Carbapenem Resistant Bacterial Infection
- Hemophagocytic Lymphohistiocytoses
- Carrimycin tablets
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Aug 4, 2023
Hemophagocytic Lymphohistiocytoses Trial in Cincinnati
Recruiting
- Hemophagocytic Lymphohistiocytoses
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Oct 25, 2022
PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)
Not yet recruiting
- PD-1 Antibody
- +3 more
- L-DEP and PD-1 antibody
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 8, 2023
Immune Function and PD-1 Antibody Therapy Efficacy Predictors on
Recruiting
- Secondary Hemophagocytic Lymphohistiocytosis
- Chronic Active Epstein-Barr Virus Infection
- No intervention
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
May 2, 2023
Hemophagocytic Lymphohistiocytosis Trial in Beijing (Venetoclax, Dexamethasone, Etoposide)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- Venetoclax
- +2 more
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Sep 15, 2022
Segmental Resection Combined With DEP Regimen for EBV-HLH
Not yet recruiting
- Hemophagocytic Lymphohistiocytosis
- +2 more
- Segmental bowel resection combined with the DEP regimen
-
Beijing, Beijing, ChinaZhao Wang
Nov 9, 2023
Haemophagocytic Lymphohistiocytosis Trial (Ruxolitinib)
Not yet recruiting
- Haemophagocytic Lymphohistiocytosis
- (no location specified)
Feb 28, 2023
Hemophagocytic Lymphohistiocytoses, EBV, Metabonomics Trial in Beijing (observational)
Not yet recruiting
- Hemophagocytic Lymphohistiocytoses
- +2 more
- observational
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Dec 22, 2022
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Not yet recruiting
- Lymphoma
- Haemophagocytic Lymphohistiocytosis
- (no location specified)
Jan 25, 2023
Hemophagocytic Lymphohistiocytoses, Lymphoma Trial in Beijing (cytokine)
Not yet recruiting
- Hemophagocytic Lymphohistiocytoses
- Lymphoma
- cytokine
-
Beijing, Beijing, ChinaZhao Wang
Oct 27, 2022
Prospective Validation of the OHI Index
Recruiting
- HLH
- +4 more
-
Kfar Saba, Israel
- +1 more
May 21, 2023
Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Trial in Worldwide (ELA026)
Recruiting
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
-
Innsbruck, Austria
- +9 more
Oct 24, 2022
Hemophagocytic Lymphohistiocytosis Trial in Philadelphia (tocilizumab)
Withdrawn
- Hemophagocytic Lymphohistiocytosis
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 11, 2022
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection Trial in Beijing (Rituximab
Recruiting
- Secondary Hemophagocytic Lymphohistiocytosis
- Chronic Active Epstein-Barr Virus Infection
- Rituximab Monotherapy
-
Beijing, ChinaZhao Wang
May 18, 2022
Hemophagocytic Syndrome Trial in Chongqing (cyclophosphamide, VP-16, Dexamethasone)
Recruiting
- Hemophagocytic Syndrome
- cyclophosphamide
- +3 more
-
Chongqing, ChinaThe Second affiliated Hosptial of Chongqing medical University
Jun 28, 2023
Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)
Not yet recruiting
- Hemophagocytic Lymphohistiocytosis
- L-DEP and PD-1 antibody
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Apr 19, 2022
Hemophagocytic Lymphohistiocytosis Trial in Beijing (DEP combine with PD-1 antibody)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- DEP combine with PD-1 antibody
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Feb 13, 2022
Hemophagocytic Lymphohistiocytosis Trial in United States (Ruxolitinib, Dexamethasone, Etoposide)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- Ruxolitinib
- +2 more
-
Phoenix, Arizona
- +9 more
Jan 9, 2023
Toxicities in Children and Adults With Cancer
Active, not recruiting
- Macrophage Activation Syndrome
- Primary Hemophagocytic Lymphohistiocytosis
-
Bethesda, MarylandNational Cancer Institute (NCI)
Sep 17, 2022
Primary Hemophagocytic Lymphohistiocytosis Trial in China (Emapalumab-Lzsg 5 MG/ML [Gamifant])
Recruiting
- Primary Hemophagocytic Lymphohistiocytosis
- Emapalumab-Lzsg 5 MG/ML [Gamifant]
-
Shanghai, Fudan, China
- +6 more
Feb 23, 2023
Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 2, 2022